Belpointe Asset Management’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$308K Buy
+5,485
New +$285K 0.01% 891
2025
Q3
Sell
-7,917
Closed -$285K 1039
2025
Q2
$285K Buy
+7,917
New +$262K 0.01% 766
2023
Q2
Sell
-24
Closed -$865 2788
2023
Q1
$865 Buy
24
+4
+20% +$148 ﹤0.01% 3497
2022
Q4
$790 Buy
+20
New +$835 ﹤0.01% 3479

Other funds holding RPRX

Belpointe Asset Management's RPRX Position: Q2 2026 in Review

Belpointe Asset Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 5,485 shares worth $308K. The stake represents 0.01% of the portfolio and ranks #891 among its holdings. This is a return to the name: Belpointe Asset Management previously reported a position in RPRX as recently as Q2 2025.

Belpointe Asset Management first reported a position in RPRX in Q4 2022 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Belpointe Asset Management held 5,485 shares of Royalty Pharma worth $308K as of Q2 2026.
  • Royalty Pharma was a new Belpointe Asset Management position in Q2 2026.
  • Royalty Pharma made up 0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #891 holding.
  • Belpointe Asset Management first reported a position in Royalty Pharma in Q4 2022 and has held it in 4 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.